Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ERBB3 mutant Cisplatin + Gemcitabine + Sorafenib invasive bladder transitional cell carcinoma predicted - sensitive detail...
PIK3CA mutant Cisplatin + Gemcitabine + Sorafenib invasive bladder transitional cell carcinoma predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01326871 Phase Ib/II ALT-801 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status USA 0
NCT02546661 Phase I AZD9150 + Durvalumab Durvalumab + Selumetinib AZD4547 Durvalumab + Olaparib Durvalumab AZD4547 + Durvalumab Durvalumab + Vistusertib Adavosertib + Durvalumab Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) Active, not recruiting USA | FRA | ESP | CAN 1
NCT02560636 Phase I Pembrolizumab Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB) Recruiting 1
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA | FRA | ESP 3
NCT03244384 Phase III Pembrolizumab Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Active, not recruiting USA 1
NCT03534804 Phase II Cabozantinib + Pembrolizumab Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab) Recruiting USA 0
NCT03549715 Phase Ib/II Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Tremelimumab + Vinblastine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO) Recruiting FRA 0
NCT03558087 Phase II Cisplatin + Gemcitabine + Nivolumab Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing Active, not recruiting USA 0
NCT03697850 Phase II Atezolizumab Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (BladderSpar) Recruiting FRA 0
NCT03747419 Phase II Avelumab Avelumab and Radiation in Muscle-Invasive Bladder Cancer Recruiting USA 0
NCT03837821 Phase I Abemaciclib Window of Opportunity Trial of Abemaciclib for Bladder Cancer Recruiting USA 0
NCT03924856 Phase III Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Gemcitabine Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 15
NCT03924895 Phase III Pembrolizumab Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 18
NCT04186013 Phase II Atezolizumab Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cancer Recruiting ESP 0
NCT04197986 Phase III Infigratinib Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 3
NCT04586244 Phase II Retifanlimab Epacadostat + Retifanlimab Epacadostat An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (Optimus) Recruiting USA | ITA | FRA 0
NCT04658862 Phase III Cisplatin Cetrelimab + TAR-200 Gemcitabine A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 20
NCT04700124 Phase III Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Gemcitabine Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15) Recruiting USA | ITA | FRA | ESP | DEU | CAN 15
NCT04871529 Phase II Avelumab + Carboplatin + Gemcitabine Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Recruiting USA 0
NCT04960709 Phase III Durvalumab + Enfortumab vedotin-ejfv + Tremelimumab Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin (VOLGA) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 21
NCT05239624 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer Recruiting USA 0
NCT05241340 Phase II PF-06801591 Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE) Recruiting USA 0